Page last updated: 2024-11-07
5-benzyloxybenzylacyclouridine
Description
5-benzyloxybenzylacyclouridine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5-benzyloxybenzylacyclouridine : A benzyl ether that consists of acyclouridine bearing a 3-(benzyloxy)benzyl substituent at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 134111 |
| CHEMBL ID | 277577 |
| CHEBI ID | 39579 |
| SCHEMBL ID | 21067979 |
| MeSH ID | M0106898 |
Synonyms (22)
| Synonym |
|---|
| 5-[3-(benzyloxy)benzyl]-1-[(2-hydroxyethoxy)methyl]pyrimidine-2,4(1h,3h)-dione |
| 5-(3-benzyloxy-benzyl)-1-(2-hydroxy-ethoxymethyl)-1h-pyrimidine-2,4-dione |
| bdbm50030980 |
| 5-bbau |
| 2,4(1h,3h)-pyrimidinedione, 1-((2-hydroxyethyoxy)methyl)-5-((3-(phenylmethoxy)phenyl)methyl)- |
| 2,4(1h,3h)-pyrimidinedione, 1-((2-hydroxyethoxy)methyl)-5-((3-(phenylmethoxy)phenyl)methyl)- |
| unii-ta375l4wsv |
| 5-(m-benzyloxybenzyl)-1-(2'-hydroxyethoxymethyl)uracil |
| ta375l4wsv , |
| 1-((2-hydroxyethoxy)methyl)-5-(3-(benzyloxy)benzyl)pyrimidine-2,4(1h,3h)-dione |
| 5-benzyloxybenzylacyclouridine |
| DB06873 |
| CHEMBL277577 , |
| chebi:39579 , |
| 82857-75-8 |
| 5-(benzyloxybenzyl)acyclouridine |
| bbau |
| Q27095778 |
| SCHEMBL21067979 |
| 5-{[3-(benzyloxy)phenyl]methyl}-4-hydroxy-1-[(2-hydroxyethoxy)methyl]pyrimidin-2(1h)-one |
| DTXSID201002966 |
| PD005825 |
Drug Classes (3)
| Class | Description |
|---|
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| benzyl ether | A compound of formula PhCH2OR (R =/= H). |
| hydroxyether | Any ether carrying a hydroxy group at unspecified position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.60 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.39 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |